Journal article icon

Journal article

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.

Abstract:

BACKGROUND: 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) is a water-soluble mitochondrial toxin that binds to adenine nucleotide translocase in the inner mitochondrial membrane, thereby targeting cell proliferation. This phase 1 study investigated safety, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and pharmacokinetics (PK) of GSAO as a daily 1-h infusion for 5 days a week for 2 weeks in every three. Pharmacodynamics of GSAO was evaluated by dynamic contrast-en...

Expand abstract
Publication status:
Published

Actions


Access Document


Publisher copy:
10.1007/s00280-013-2320-9

Authors


More by this author
Institution:
University of Oxford
Division:
MPLS
Department:
Engineering Science
Sub department:
Institute of Biomedical Engineering
Role:
Author
Expand authors...
Journal:
Cancer chemotherapy and pharmacology
Volume:
72
Issue:
6
Pages:
1343-1352
Publication date:
2013-12-01
DOI:
EISSN:
1432-0843
ISSN:
0344-5704
Source identifiers:
436121

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP